Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and SCAN domain-containing protein 30 (ZSCAN30) is a protein-coding gene and transcription factor belonging to the zinc finger protein family. It contains both C2H2-type zinc finger domains and a SCAN domain, which are characteristic features mediating DNA-binding and protein-protein interactions, respectively. ZSCAN30 is predicted to function as a DNA-binding transcription factor specific for RNA polymerase II, regulating transcription from RNA polymerase II promoters. The protein is primarily localized to the nucleus. ZSCAN30 is expressed at low tissue specificity and is most closely associated with transcriptional regulation. Paralogous to ZNF397, it is part of the broader family of zinc finger transcription factors that modulate gene expression. Disease association has been noted with pancreatic acinar cell adenocarcinoma, but no direct evidence exists for its use as a therapeutic target, biomarker, or for involvement with approved drugs or small molecules[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and SCAN domain-containing protein 30 (ZSCAN30).